Icos-Texas Biotech start pivotal trial

Icos-Texas Biotechnology, a joint venture between Icos (ICOS) and Texas Biotech (TXB) started a North American Phase II/III trial of its sitaxsentan once daily oral endothelin-A receptor antagonist in...